Taysha Gene Therapies/$TSHA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Taysha Gene Therapies
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Ticker
$TSHA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
73
ISIN
US8776191061
Website
TSHA Metrics
BasicAdvanced
$511M
-
-$0.33
1.02
-
Price and volume
Market cap
$511M
Beta
1.02
52-week high
$3.24
52-week low
$1.05
Average daily volume
4.7M
Financial strength
Current ratio
5.351
Quick ratio
5.169
Long term debt to equity
108.649
Total debt to equity
108.149
Interest coverage (TTM)
-909.91%
Profitability
EBITDA (TTM)
-82.509
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,201.08%
Operating margin (TTM)
-1,158.80%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-35.91%
Return on equity (TTM)
-159.34%
Valuation
Price to revenue (TTM)
85.544
Price to book
8.86
Price to tangible book (TTM)
8.86
Price to free cash flow (TTM)
-7.352
Free cash flow yield (TTM)
-13.60%
Free cash flow per share (TTM)
-32.37%
Growth
Revenue change (TTM)
-48.97%
Earnings per share change (TTM)
-55.22%
3-year earnings per share growth (CAGR)
-59.64%
What the Analysts think about TSHA
Analyst ratings (Buy, Hold, Sell) for Taysha Gene Therapies stock.
Bulls say / Bears say
Taysha Gene Therapies has secured a strategic investment of $50 million from Astellas Pharma, acquiring 15% of the company and exclusive options to license TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy, indicating strong industry confidence in Taysha's pipeline. (tayshagtx.com)
The appointment of Sean P. Nolan, former CEO of AveXis, as Taysha's new CEO brings experienced leadership in gene therapy commercialization, potentially accelerating the development and market entry of Taysha's therapies. (dallasinnovates.com)
Taysha's lead program, TSHA-102 for Rett syndrome, has received multiple regulatory designations, including Regenerative Medicine Advanced Therapy and Fast Track from the FDA, which could expedite its development and approval process. (tayshagtx.com)
Despite a reduction in net loss, Taysha reported a net loss of $89.3 million for the full year ended December 31, 2024, indicating ongoing financial challenges. (tayshagtx.com)
The gene therapy sector faces significant regulatory hurdles and competition, which could delay Taysha's product approvals and market entry, impacting revenue generation. (tayshagtx.com)
Taysha's reliance on partnerships, such as the one with Astellas, may lead to potential dilution of control over its key assets and future revenues. (tayshagtx.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
TSHA Financial Performance
Revenues and expenses
TSHA Earnings Performance
Company profitability
TSHA News
AllArticlesVideos
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
GlobeNewsWire·4 weeks ago
Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?
Benzinga·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Taysha Gene Therapies stock?
Taysha Gene Therapies (TSHA) has a market cap of $511M as of June 30, 2025.
What is the P/E ratio for Taysha Gene Therapies stock?
The price to earnings (P/E) ratio for Taysha Gene Therapies (TSHA) stock is 0 as of June 30, 2025.
Does Taysha Gene Therapies stock pay dividends?
No, Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Taysha Gene Therapies dividend payment date?
Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Taysha Gene Therapies?
Taysha Gene Therapies (TSHA) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.